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Inappropriate Gene Activation in FSHD:
A Repressor Complex Binds a Chromosomal
Repeat Deleted in Dystrophic Muscle
patients carry fewer than 11 repeats (Lunt, 1998). The
number of D4Z4 repeats is a critical determinant of the
age of onset and clinical severity of FSHD (Goto et al.,
1995; Lunt et al., 1995; Zatz et al., 1995; Tawil et al.,
1996; Hsu et al., 1997; Ricci et al., 1999). In general, 1–3
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27100 Pavia Two candidate genes, FRG1 and TUB4q, were iso-
lated from the FSHD critical region, but their role inItaly
FSHD pathogenesis has failed to be substantiated (van
Deutekom et al., 1996; van Geel et al., 2000). Recently,
a new gene, FRG2, mapping 37 kb proximal to D4Z4, hasSummary
been discovered (R.R. Frants, personal communication),
although its biological function has not been elucidated.Facioscapulohumeral muscular dystrophy (FSHD), a
common myopathy, is an autosomal dominant disease In addition, a putative open reading frame (DUX4) within
D4Z4 has been identified (Gabriels et al., 1999), but thereof unknown molecular mechanism. Almost all FSHD
patients carry deletions of an integral number of tandem is no evidence that it is expressed.
Some normal individuals carry an abnormal chromo-3.3 kilobase repeats, termed D4Z4, located on chromo-
some 4q35. Here, we find that in FSHD muscle, 4q35 some 4 resulting from an unbalanced translocation be-
tween the 4q35 subtelomeric region and the short armgenes located upstream of D4Z4 are inappropriately
overexpressed. We show that an element within D4Z4 of an acrocentric chromosome (Tupler et al., 1996). The
rearranged chromosome 4 lacks the entire D4Z4 repeatspecifically binds a multiprotein complex consisting of
YY1, a known transcriptional repressor, HMGB2, an ar- and a 200 kb proximal region including FRG2, TUB4q,
and FRG1. Thus, haploinsufficiency of the entire 4qchitectural protein, and nucleolin. We demonstrate
that this multiprotein complex binds D4Z4 in vitro and subtelomeric region has no phenotypic consequence,
whereas deletion of only the D4Z4 repeats is associatedin vivo and mediates transcriptional repression of 4q35
genes. Based upon these results, we propose that with FSHD. Collectively, these results suggest that
FSHD results from a gain-of-function mutation and raisedeletion of D4Z4 leads to the inappropriate transcrip-
tional derepression of 4q35 genes resulting in disease. the possibility that 4q35 genes proximal to D4Z4 play a
role in disease initiation or progression.
These observations strongly suggest that FSHD is notIntroduction
the result of a classical mutation within a protein-coding
gene. We have previously reported that in FSHD muscleFacioscapulohumeral muscular dystrophy (FSHD) is the
third most common inherited myopathy, with an inci- many genes are transcriptionally misregulated, raising
the possibility that a regulatory defect might be the un-dence of 1:20,000 (Padberg, 1982). The disease is char-
acterized by progressive weakness and atrophy of the derlying basis of disease (Tupler et al., 1999). Here we
investigate the possibility that deletion of D4Z4 repeatsfacial and shoulder girdle muscles, which subsequently
spreads to the abdominal and pelvic girdle muscles with initiates transcriptional misregulation.
highly variable expression. The genetic defect follows
autosomal dominant inheritance, although new muta- Results
tions account for approximately 10% of recognized
cases (Lunt, 1998). Inappropriate Overexpression of 4q35 Genes
The FSHD locus was mapped to the subtelomeric in FSHD Dystrophic Muscle
region of the long arm of chromosome 4, 4q35, by ge- To investigate whether altered expression of 4q35 genes
netic linkage analysis (Sarfarazi et al., 1992). Almost all could be the underlying basis of FSHD, we collected
FSHD patients carry rearrangements occurring in a 3.3 human muscle samples from normal individuals and pa-
kilobase (kb) tandemly repeated sequence (D4Z4) lo- tients affected by FSHD as well as several other muscu-
cated at the 4q subtelomeric region (Wijmenga et al., lar dystrophies including Duchenne muscular dystrophy
1992). These rearrangements result in EcoRI alleles (DMD), amyotrophic lateral sclerosis (ALS), and limb gir-
shorter than 35 kb, providing the molecular marker for dle muscular dystrophy type 2 (LGMD). Expression of
FSHD diagnosis (Lunt, 1998). three 4q35 genes, FSHD region gene 1 (FRG1), FSHD
D4Z4 is highly polymorphic with a variable number region gene 2 (FRG2), and the adenine nucleotide trans-
tandem repeat (VNTR) structure (Hewitt et al., 1994; Wi- locator-1 gene (ANT1), was analyzed by RT-PCR.
nokur et al., 1994). In the general population, its size Figure 1A shows that expression of FRG2, the gene
may vary between 11 and 150 units, whereas FSHD most proximal to D4Z4, was undetectable in normal
muscle but was present at a significant level in all three
FSHD muscle samples. Expression of the two other 4q353 Correspondence: rossella.tupler@umassmed.edu
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genes, FRG1 and ANT1, was detected in all muscle
samples but overexpressed only in FSHD muscle. Quan-
titation by phosphoimager analysis revealed, first, that
in normal muscle the expression level of 4q35 genes
increased with distance from D4Z4 and, second, that in
FSHD muscle the level of overexpression varied in-
versely with distance from D4Z4. Glyceraldehyde Phos-
phate Dehydrogenase (GAPDH), which is not at 4q35,
was expressed equivalently in all muscle samples. Sig-
nificantly, Figure 1B shows that in lymphocytes from
FSHD patients, expression of FRG2, FRG1, and ANT1
was equivalent to that observed in normal tissue, indi-
cating that overexpression of 4q35 genes in FSHD is
muscle specific. Expression of 4q35 genes was also
normal in DMD, ALS, and LGMD muscle samples (Figure
1C), indicating that misregulated 4q35 gene expression
is not a general characteristic of muscular dystrophies.
As described above, the number of D4Z4 repeats is
a critical determinant of disease severity (Ricci et al.,
1999). The results of Figures 1A–1C raised the possibility
that inappropriate overexpression of 4q35 genes lo-
cated upstream of D4Z4 was the underlying basis of
FSHD. A prediction of this model is that 4q35 gene
overexpression would be increased when the number
of D4Z4 repeats is decreased. To test this prediction,
we analyzed expression of FRG2 in muscle biopsies
from six additional FSHD patients carrying varying num-
bers of D4Z4 repeats. The results of Figure 1D clearly
demonstrate that the level of FRG2 overexpression is
indeed inversely related to the number of D4Z4 repeats.
On the basis of Figures 1A–1D, we conclude that 4q35
gene mRNAs and presumably proteins are overex-
pressed in FSHD muscle in a manner inversely related
to distance from D4Z4 and the number of D4Z4 repeats.
Detection of a Nuclear Activity that Binds to D4Z4
The most likely mechanism by which D4Z4 could sup-
press 4q35 gene transcription is through interaction with
a cellular factor (or factors) that silences the expression
of nearby genes. We tested this possibility by analyzing
the interaction between D4Z4 and nuclear proteins using
an electrophoretic mobility shift assay (EMSA). Probes
were generated by 32P-end-labeling eight restriction en-
zyme-digested fragments that spanned the entire D4Z4Figure 1. Inappropriate Overexpression of 4q35 Genes in FSHD
sequence. Figure 2A shows that one DNA fragment,Dystrophic Muscle
termed D4Z4-243, supported formation of a specific(A) FRG2, FRG1, and ANT1 expression analysis was performed on
RNA extracted from muscles derived from three normal individuals complex. This complex was abolished by addition of
(Normal 1–3) and three FSHD patients (FSHD 1–3) by radioactive increasing amounts of D4Z4-243 DNA but not by non-
RT-PCR using specific primers. Results are presented for three of specific DNA (Figure 2B). A comparable D4Z4-243 bind-
three total FSHD patients analyzed. GAPDH expression was also ing activity was also detected in nuclear extracts pre-
monitored and used for sample normalization. Signal intensity was
pared from several human and mouse myogenic cellquantitated by phosphoimager analysis; the expression level of each
lines (see below and data not shown).gene in normal muscle (top right) and the ratio of expression levels
in FSHD and normal muscle (bottom right) are shown. (Bottom) Deoxyribonuclease I (DNase I) footprinting was used
Schematic representation of 4q35 showing physical distances be- to map the binding site within D4Z4-243. Figure 2C
tween the genes in megabases (Mb), which were established based shows that following incubation with nuclear extracts
on the chromosome map published at http://www.ncbi.nlm.nih.gov,
and the localization of FRG1, FRG2 and D4Z4 within the AF146191-
U85056 contig.
(B) FRG2, FRG1, ANT1, and GAPDH expression analysis was per-
(D) Analysis of FRG2 and GAPDH expression in muscle from twoformed on RNA extracted from peripheral blood lymphocytes (PBL)
additional normal (Normal 6 and 7) and six additional FSHD patientsof the same normal and FSHD patients as in (A) by radioactive RT-PCR.
(FSHD 4–9) carrying the indicated number of D4Z4 repeats. Signal(C) Analysis of FRG2, FRG1, ANT1, and GAPDH expression in muscle
intensity was quantitated by phosphoimager analysis and normal-from two other normal individuals (Normal 4 and 5) and patients
ized based upon to GAPDH signal; the ratios of expression levelsaffected by Duchenne Muscular Dystrophy (DMD), Amyotrophic Lat-
between FSHD muscles and normal muscle (right) are shown.eral Sclerosis (ALS), and Limb Girdle Muscular Dystrophy type 2
(LGMD) patients.
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Figure 2. Detection of a Nuclear Activity that Binds to D4Z4
(A) Electrophoretic mobility shift assay (EMSA). Each fragment was end-labeled, incubated with () or without () HeLa nuclear extract for
30 min, and fractionated on nondenaturing polyacrylamide gels. The specific shift with probe 243 is indicated by the arrowhead; the nonspecific
shifts are indicated by asterisks; the position of the free probe is indicated by the bracket. (Bottom) Schematic representation of the 3.3 kb
D4Z4 KpnI unit, showing the positions of the restriction enzyme sites KpnI (K), PstI (P), and EagI (E), as well as the fragment sizes generated
by enzyme digestion.
(B) The D4Z4-243 probe was incubated with () or without () nuclear extract, in the presence of molar excess of cold specific or nonspecific
competitor as indicated. The mobility shift is indicated by the arrowhead, and the position of the free probe is indicated by the bracket.
(C) In vitro DNase I footprinting. D4Z4-243 was end-labeled and incubated with or without DNase I for 1 min in the presence or absence of
increasing quantities of either HeLa, C2C12 myoblast, or C2C12 myotube nuclear extract. The black bar represents the protected region, and
the corresponding 27 bp sequence is indicated. A GA sequencing ladder (not shown) run in parallel with the footprinting reactions was used
to orient the sequence.
from HeLa cells, C2C12 myoblasts, or C2C12 myotubes, of G418-resistant colonies decreased by 25%, 45%, and
86%, respectively. Significantly, insertion of a nonre-a 27 basepair (bp) sequence (CCATTCATGAAGGGGTG
GAGCCTGCCT) within D4Z4-243 was protected from lated spacer sequence had no effect, indicating that
the decrease in colony number was not simply due toDNase I digestion. We will refer to this 27 bp sequence
as the D4Z4 binding element (DBE). increased distance between the CMV promoter and the
reporter gene. On the basis of these results, we conclude
that the DBE within D4Z4 is a transcriptional repressionThe DBE Is a Transcriptional Repression Element
One explanation for the results presented above is that element.
the DBE is a transcriptional repression element that,
when deleted in FSHD, leads to overexpression of 4q35 Identification of a Multiprotein Complex that Binds
to the DBEgenes. To test this hypothesis, we analyzed the ability
of the DBE to suppress transcription of a reporter gene To identify and characterize proteins that bind to the
DBE, we biochemically purified the D4Z4 recognitionexpressed from the strong cytomegalovirus (CMV) pro-
moter. Analogous assays have been used previously to complex (DRC) using sequential chromatography of
HeLa nuclear extracts on P11 Phosphocellulose, DEAE-identify positive and negative transcriptional regulatory
elements (see, for example, Chung et al., 1997). Sepharose, and DBE-Agarose (see Figure 4A, sche-
matic). The purified DRC was fractionated on an SDS-We constructed a series of plasmids in which increas-
ing numbers of DBEs were inserted between the CMV PAGE gel, and the polypeptides were detected by silver
staining, excised, and microsequenced by mass spec-promoter and the neomycin-resistance gene. The plas-
mids were stably transfected into HeLa cells, and the trometry. Figure 4A shows that four bands were present
in the active fraction: YY1, a multifunctional repressor/number of G418-resistant colonies was quantitated. As
shown in Figure 3, the number of inserted DBEs inversely activator (reviewed in Thomas and Seto, 1999); HMGB2,
a member of a family of nonhistone chromatin-associ-correlated with the number of G418-resistant colonies:
in the presence of one, two, or six DBEs, the number ated proteins (reviewed in Thomas and Travers, 2001);
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the DBE and bound proteins. DNA-protein complexes
were then immunopurified using antibodies directed
against various DRC components, and the presence of
specific DNA fragments in the immunoprecipitate was
quantified by PCR. We used three sets of primer pairs
that were specific to either D4Z4, p13E-11, or FRG1.
Figure 5A shows that all three DRC components, YY1,
HMGB2, and nucleolin, were associated with D4Z4 se-
quences. In contrast, there was no detectable binding
of any DRC component to the control sequences
p13E-11 or FRG1.
The human genome contains sequences homologous
to D4Z4 on several chromosomes in addition to 4 (Wij-Figure 3. The DBE Is a Transcriptional Repression Element
menga et al., 1992; Winokur et al., 1994; Lyle et al.,(Left) Schematic representation of the reporter constructs con-
1995). It was therefore possible that the interaction be-taining the CMV promoter driving expression of the neomycin-resis-
tance reporter gene (NEO). One, two, or six copies of the 27 bp tween the DRC and DBE detected in the ChIP assay
minimal D4Z4 binding element (DBE) were inserted between the shown in Figure 5A did not occur at 4q35, but rather at
CMV promoter and the transcription start site of the NEO gene, one or more of these other chromosomal loci. To ad-
which is indicated by the arrow. A construct containing a pBluescript
dress this possibility, we used the ChIP assay to analyzespacer equivalent in length to the size of the insert generated by
binding to the DBE in a human/rodent monochromoso-six copies of the DBE was also included as a control.
mal cell hybrid containing a single human chromosome(Right) HeLa cells were stably transfected and grown in medium
containing G418. G418-resistant colonies were counted after 2 4. The rodent genome lacks D4Z4 repetitive sequences
weeks; the number of colonies obtained with each construct is (Clark et al., 1996), and therefore in this experimental
shown relative to the number of colonies obtained for the construct system the only genomic copy of D4Z4 is present at 4q
lacking D4Z4 binding sites.
of the human chromosome. Figure 5B shows that in this
cell line, all three DRC components were specifically
associated with the D4Z4 sequences. On the basis ofnucleolin; and keratin. Keratin is a common contaminant
these results, we conclude that in vivo the DRC is boundof mass spectrometric analysis (Eng et al., 1994) and was
to D4Z4 within 4q35.not further analyzed. Immunoblot analysis confirmed the
identity of YY1, HMGB2, and nucleolin (Figure 4A).
Reducing the Levels of DRC Components ResultsTo verify that this multiprotein complex was in fact the
in Overexpression of 4q35 Genesnuclear DBE binding activity, mobility-shift experiments
The results presented above suggest that deletion ofwere performed using antibodies directed against YY1,
D4Z4 repeats reduces the number of DBEs and thus theHMGB2, and nucleolin. Figure 4B shows that antibodies
number of DNA bound DRCs present at 4q35. Reducingto nucleolin and HMGB2 resulted in formation of a lower
the number of bound transcriptional repressing com-mobility complex (“supershift”), whereas addition of a
plexes is predicted to result in the inappropriate upregu-control antibody had no effect. An antibody to YY1 inter-
lation of 4q35 genes. To verify that the DRC is responsi-fered with formation of the DBE mobility shift, sug-
ble for the lack of 4q35 gene expression in normal cells,gesting that association of YY1 with either a component
we performed antisense experiments to decrease theof the DRC or the DBE itself had been disrupted.
intracellular levels of DRC components.
HeLa cells were transfected with morpholino oligonu-Recognition of the DBE by YY1
cleotides targeted to human YY1, HMGB2, or nucleolinWe noticed that the DBE contains a putative YY1 recog-
mRNA. The immunoblot in Figure 6A shows that eachnition sequence (CCATN; Yant et al., 1995), suggesting
antisense oligonucleotide specifically reduced the levelthat YY1 directly interacts with the DBE. To test this
of its cognate protein. Figure 6B shows that reducingpossibility, we carried out mobility-shift experiments us-
the levels of YY1, HMGB2, or nucleolin resulted in over-ing recombinant YY1. Figure 4C shows that recombinant
expression of the 4q35 gene FRG2. Thus, reducing theGST-YY1, but not GST alone, bound the DBE probe. A
levels of DRC components recapitulates the molecularDBE probe containing a mutation within the YY1 core
event observed at 4q35 in FSHD muscle.recognition sequence was not bound by GST-YY1.
Moreover, this mutant probe failed to support a mobility
shift with HeLa nuclear extract (Figure 4C, right), sug- Discussion
gesting that elimination of YY1 binding also abolished
association of the entire DRC to the DBE. We conclude A Model for the Molecular Basis of FSHD
FSHD is a complex disease with a peculiar involvementthat YY1 has an intrinsic DBE binding activity and that
YY1 is the most likely DRC component to directly con- of muscle groups, highly variable severity, and unpre-
dictable progression. The disease has been causallytact the DBE.
related to deletion of subtelomeric D4Z4 repeats at
4q35; however, no candidate gene has been isolated.The DRC Binds D4Z4 In Vivo
To determine whether the DRC also binds D4Z4 se- The failure to identify an expressed sequence in this
region has prompted an alternative model that proposesquences in vivo, we performed chromatin immunopre-
cipitation (ChIP) experiments. HeLa cells were first the disease is due to the inappropriate expression of
nearby genes by a positional effect. According to thistreated with formaldehyde to induce crosslinks between
Molecular Basis of FSHD
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Figure 4. Identification of a Multiprotein Com-
plex that Binds to the DBE
(A) Schematic representation of the chro-
matographic steps used to purify the D4Z4
binding activity. HeLa nuclear extracts were
fractionated first on a P11 Phosphocellulose
column, and the active fraction, as monitored
by EMSA, was subsequently fractionated on
a DEAE-Sepharose column. Active fractions
(bracketed lanes) were pooled and loaded
onto a DBE affinity resin; the active fractions
from this step were pooled and fractionated
again on a fresh DBE affinity column. Final
active fractions (bracketed lanes) were
pooled and separated by SDS-PAGE, and
four bands were detected by silver staining
(left). Mass spectrometry analysis identified
the bands as nucleolin, YY1, keratin, and
HMGB2, as shown. The mass spectrometry
results were confirmed by immunoblotting
(right).
(B) EMSA was performed in the presence of
antibodies specific to each DRC component,
or in the presence of the control antibody
IgG. Anti-YY1 antibodies immunocompeted
the mobility shift, while anti-Nucleolin and
anti-HMGB2 antibodies generated a su-
pershift (indicated by the arrow).
(C) Recognition of the DBE by YY1 in vitro.
EMSA was performed with purified GST-YY1
(left) or nuclear extract (right) using a wild-
type (wt) DBE probe or a version mutated in
the YY1 recognition sequence, as shown.
model, deletion of D4Z4 places the normally euchro- a function of the number of deleted D4Z4 repeats (Figure
1D), which is also a critical determinant of disease sever-matic genes in 4q35 under the control of telomeric het-
erochromatin, thereby leading to their transcriptional ity (Ricci et al., 1999). The 4q35 gene overexpression
model of Figure 7 provides a molecular explanation forrepression (Fisher and Upadhyaya, 1997).
Based on the results presented in this study, we pro- the autosomal dominant transmission of FSHD. Our find-
ing that 4q35 gene overexpression is muscle specificpose a different model for the molecular basis of FSHD
(Figure 7). In normal individuals, the presence of a (Figure 1B) also provides an attractive explanation for
the tissue specificity of the disease. However, it is impor-threshold number of D4Z4 repeats leads to repression
of 4q35 genes by virtue of a DNA bound multiprotein tant to recognize that FSHD is a complex disorder, and
in addition to overexpression of 4q35 genes, factorscomplex that actively suppresses gene expression. In
FSHD patients, deletion of an integral number of D4Z4 such as the allelic variability of 4q35 genes, gender, and
environment may also affect disease onset and severity.repeats reduces the number of bound repressor com-
plexes and consequently decreases (or abolishes) tran- The precise basis by which overexpression of 4q35
genes results in FSHD remains to be determined. De-scriptional repression of 4q35 genes. As a result, these
genes are inappropriately overexpressed, ultimately tailed analysis of the sequence surrounding the D4Z4
repeats has revealed it to be a relatively gene-poor re-leading to disease onset and progression. We have
shown that the extent of transcriptional derepression is gion with a high density of pseudogenes and repetitive
Cell
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Figure 5. The DRC Binds D4Z4 In Vivo
(A) Chromatin immunoprecipitation (ChIP)
analysis of D4Z4 binding in HeLa cells. Fol-
lowing formaldehyde crosslinking, purified
chromatin was immunoprecipitated with anti-
bodies to YY1, nucleolin, or HMGB2 or with
a nonspecific antibody, and the purified DNA
was analyzed by quantitative PCR using
primers specific for D4Z4, p13E-11, or FRG1.
The signal in the immunoprecipitate (IP) was
quantitated by phosphoimager analysis and
expressed as the fraction of the starting (IN-
PUT) material.
(B) ChIP analysis in a human/rodent mono-
chromosomal cell hybrid containing a single
human chromosome 4 such that the only ge-
nomic copy of D4Z4 is present at human
4q35. Samples were treated and analyzed as
described in (A). (Bottom) Schematic repre-
sentation of the analyzed region showing the
relative positions of D4Z4, p13E-11, and
FRG1.
elements (van Geel et al., 1999; Blair et al., 2002). Al- cle, lack homologies with other protein and contain no
recognizable protein motifs. By far the best candidatethough a number of short genes have been predicted
by bioinformatic analyses, their existence has not been for an FSHD-inducing gene is ANT1, which encodes
an adenine nucleotide translocator. ANT1 is a centralconfirmed by either expressed sequence tag database
searches or RT-PCR (our unpublished data). component of the mitochondrial permeability transition
pore complex and is predominantly expressed in heartAmong the known 4q35 genes, FRG1 and FRG2,
which we have shown are overexpressed in FSHD mus- and skeletal muscle. ANT1 mutations have been found
in patients with progressive external ophthalmoplegia,
an autosomal dominant myopathy (Kaukonen et al.,
2000; Napoli et al., 2001), and ANT1 is upregulated in
certain cardiomyopathies (Dorner and Schultheiss,
2000). Most importantly, ANT1 overexpression induces
apoptosis (Bauer et al., 1999); increased apoptosis is a
feature of dystrophic muscles (Tews and Goebel, 1997),
including FSHD muscle (Sandri et al., 2001). Muscle
weakness, the cardinal feature of all myopathies, is due
to reduced number of muscle fibers. Therefore, an at-
tractive model for FSHD pathogenesis is that overex-
pression of ANT1 induces apoptosis in muscle fibers,
thereby reducing their number and resulting in disease.
The DRC Binds D4Z4 and Represses Transcription
of 4q35 Genes
We found that the DRC is composed of YY1, HMGB2,
and nucleolin and associates with D4Z4 sequences both
in vitro and in vivo. In vitro binding assays demonstrated
that association of the complex with D4Z4 was mediated
through specific contacts between YY1 and a 27 bp
element contained within D4Z4. These data suggest that
YY1 is the major protein responsible for DNA binding,
although other DRC components could contribute to
DNA binding affinity and specificity. Significantly, de-
creasing the intracellular level of any one of the three
DRC proteins derepressed 4q35 gene transcription, in-
Figure 6. Reducing the Levels of DRC Components Results in Over- dicating that all three components are required for a
expression of 4q35 Genes functional silencing complex.
(A) HeLa cells were transfected with morpholino antisense oligonu- YY1, HMGB2, and nucleolin have been previously im-
cleotides specific for YY1, HMGB2, or nucleolin or with a control plicated in gene regulation and in particular transcrip-
morpholino oligonucleotide. Immunoblot analysis was performed to tional repression. YY1 is a complex protein involved in
confirm the specific reduction in the level of each protein following
both repressing and activating a number of genes. Thetransfection.
role of YY1 in repressing gene transcription is thought(B) FRG2 and GAPDH expression analysis was performed by RT-
PCR analysis on RNA extracted from the transfected cells. to be mediated through interactions with corepressors
Molecular Basis of FSHD
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Figure 7. A Model for the Molecular Basis of FSHD
In normal individuals, the presence of a threshold number of D4Z4 repeats leads to repression of 4q35 genes by virtue of a DNA bound
multiprotein complex that actively suppresses gene expression. In FSHD patients, deletion of an integral number of D4Z4 repeats reduces
the number of bound repressing complexes and consequently decreases (or abolishes) transcriptional repression of 4q35 genes. As a result,
these genes are inappropriately overexpressed, ultimately leading to disease onset and progression.
such as histone deacetylases (Thomas and Seto, 1999). A second noteworthy similarity is that repression var-
ies as a function of chromosome position. Yeast telo-HMGB2 is a member of a family of nonhistone nuclear
proteins that modulate chromatin architecture (Thomas meric silencing is initiated at the chromosome terminus
and, in general, decreases as a function of distance fromand Travers, 2001). Interestingly, HMGB2 has previously
been shown to interact with two other proteins, SP100 the telomere (Renauld et al., 1993). Similarly, we have
found a relationship between the distance of the geneand HP1, to form a transcriptional repressing complex
(Lehming et al., 1998). Nucleolin has been shown to be from the 4q telomere and transcriptional repression (Fig-
ure 1). Recent studies have shown that silencing at yeasta component of several transcription factor complexes
(Hanakahi et al., 1997; Ying et al., 2000; Schulz et al., telomeres is discontinuous, with repression occurring
only in limited domains (Pryde and Louis, 1999). Whether2001) and to interact with other nuclear components
potentially involved in the regulation of gene expression 4q35 genes in addition to FRG1, FRG2, and ANT1 are
repressed remains to be determined.including YY1 (Xie et al., 1998).
The mechanistic basis by which the DRC represses
transcription remains to be determined. One possibility
A Role for DNA Repetitive Elementsis that the D4Z4 bound DRC could directly interact with
Our results provide insights into the biological functionand block the function of the general transcription ma-
of DNA repetitive elements in gene transcription andchinery. Alternatively, the D4Z4 bound DRC could act
their potential role in human diseases. D4Z4 has a VNTRby establishing a repressive chromatin structure. The
structure: each 3.3 kb repeat contains two homeoboxes,fact that multiple 4q35 genes are repressed and that
and two different classes of human repetitive sequencesrepression can occur over a long distance leads us to
(Hewitt et al., 1994). In FSHD, D4Z4 “short” alleles arefavor the possibility that D4Z4 initiates formation of a
strictly associated with the disease. Moreover, a grouprepressive chromatin structure that can be propagated
of VNTR alleles in the promoter of the insulin gene areto repress 4q35 genes located even at distal sites.
found in linkage disequilibrium with Type 1 insulin-
dependent diabetes mellitus (Bennett et al., 1995), corre-Parallels between Transcriptional Repression
lated with insulin transcription level (Kennedy et al.,of 4q35 Genes and Yeast Telomeric Silencing
1995), and associated with birth size (Dunger et al.,Transcriptional repression at D4Z4 bears several paral-
1998). Similarly, a VNTR located downstream from thelels to telomeric silencing in yeast. The most notable
human proto-oncogene HRAS1 has been implicated insimilarity is the presence of repetitive cis-acting DNA
bladder cancer (Krontiris et al., 1993). It is tempting toelements that function as binding sites for transcrip-
speculate that these repetitive elements have a role intional repressing complexes. In yeast, the telomeric re-
regulating gene expression, analogous to those in D4Z4.peat sequences present at the chromosome terminus
contain binding sites for the repressor/activator protein
Rap1p. DNA bound Rap1p recruits additional factors, Experimental Procedures
known as the Sir proteins, which in turn interact with
Cell Lines, Cell Culturespecific histone isoforms to assemble a silencing com-
HeLa and C2C12 mouse myoblast cell lines were obtained from theplex (reviewed in Lustig, 1998). Similarly, each D4Z4
American Type Culture Collection. GM10115 (Coriell Cell Repositor-repeat unit contains a binding site for YY1, a multifunc-
ies) is a human/chinese hamster somatic cell hybrid retaining human
tional repressor/activator protein that associates with chromosome 4. HeLa and C2C12 cell lines were routinely cultured
at least two other proteins, HMGB2 and nucleolin, to in a humidified atmosphere at 37C with 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal calfform a transcriptional repressing complex.
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serum (FCS), 2 mM glutamine, and 70 g/ml gentamycin. GM10115 0.5 Tris-borate-EDTA (TBE) that had been preelectrophoresed for
30 min at 20 mA. After electrophoresis for 1.5–2 hr at 20 mA, thecells were cultured in the same media containing 0.2 mM proline.
gels were dried and exposed for autoradiography.
Antibodies
Primary antibodies used for immunoblotting and chromatin IP ex- DNase I In Vitro Footprinting
DNase I in vitro footprinting experiments were performed essentiallyperiments were obtained as follows: -YY1 and -nucleolin from
Santa Cruz, -HMGB2 from BD Transduction Laboratories, and as described (Ausubel et al., 2001). D4Z4-243 cloned in pBluescript
SK vector (Stratagene) was used as probe. Briefly, the vector was-tubulin from Sigma. The 7G2 monoclonal -nucleolin antibody
was kindly provided by S. Pinol-Roma. digested with Asp718, labeled with Klenow in the presence of
[-32P]dATP and [-32P]dCTP, digested with SacI, and gel purified.
DNA binding reactions were carried out as for EMSA in the presencePurification of the D4Z4 Binding Proteins
of different amounts of nuclear extracts. After a 30 min incubationHeLa nuclear extracts were prepared according to standard proto-
on ice, 0.3 units of DNase I (RQ1, Promega) was added and thecols (Ausubel et al., 2001) and dialyzed against dialysis buffer (20
samples incubated 1 min at room temperature. Reactions weremM HEPES [pH 8], 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.2
stopped, and phenol was extracted, precipitated, and resuspendedmM PMSF, 0.5 mM DTT). Sixty milliliters of nuclear extract (360
in formamide loading buffer. Samples were loaded onto 6% denatur-mg of protein) was fractionated on 30 ml of P11 Phosphocellulose
ing polyacrylamide gels along with sequencing reactions prepared(Whatman) using a 0.1–1 M KCl step gradient in dialysis buffer. The
as described (Ausubel et al., 2001). After electrophoresis the gelsactive fraction was dialyzed against dialysis buffer and fractionated
were dried and exposed for autoradiography.on 1 ml of DEAE-Sepharose (Pharmacia) using a 0.1–1 M KCl linear
gradient in dialysis buffer. Active fractions were pooled, dialyzed
against binding buffer 50 (20 mM HEPES [pH 8], 10% glycerol, 50 Chromatin Immunoprecipitation (ChIP)
ChIP analysis was performed according to published proceduresmM KCl, 0.2 mM EDTA, 0.2 mM PMSF, 0.5 mM DTT), and loaded
onto a DNA affinity resin prepared by coupling the D4Z4 minimal (Boyd et al., 1998; the protocol was kindly provided by P.J. Farnham).
Quantitative PCR was performed as previously described (Orlandobinding site to CNBr-activated Sepharose 4B (Pharmacia) according
to standard protocols (Ausubel et al., 2001). This column was eluted and Paro, 1993) using an aliquot (1/30) of the purified DNA. PCR
reactions contained [-32P]dATP (2.5 Ci for each 25 l reaction),using a 0.05–1 M KCl linear gradient in binding buffer 50. Active
fractions were pooled, dialyzed against binding buffer 150 (20 mM and the PCR products were detected by autoradiography after separa-
tion on a 6% polyacrylamide gel. Sequences of the oligonucleotidesHEPES [pH 8], 10% glycerol, 150 mM KCl, 0.2 mM EDTA, 0.2 mM
PMSF, 0.5 mM DTT), and fractionated on a new D4Z4 affinity column used are as follows: D4Z4 region, DBS-I (5-AGGCCTCGACGCCCTGG
GTC-3) and DBS-II (5-TCAGCCGGACTGTGCACTGCGGC-3);using a 0.15–1 M KCl linear gradient in binding buffer 150. For
peptide sequencing, 0.1 ml of a final active fraction (representing p13E-11 region, p13-I (5-AGCCCTGCCACAGGCTTCTGTG-3) and
p13-II (5-AGTGCTTATGCCTGAGGAATCTG-3); FRG1, FRG1-1f1/20 of the final yield) was resolved by 12% SDS-PAGE. Following
staining with Silver Staining Plus (BioRad), the protein bands were (5-TCTACAGAGACGTAGGCTGTCA-3) and FRG1-1rb (5-CTTGAG
CACGAGCTTGGTAG-3).excised from the gel and analyzed by MALDI-TOF Mass Spectrome-
try at the University of Massachusetts Medical School Protein Micro-
sequencing and Mass Spectrometry Center. RNA Extraction and RT-PCR
Total RNA was prepared using the TRI Reagent (Sigma) according
to the manufacturer’s instructions for the isolation of RNA for RT-Immunoblot Analysis
Total lysates were obtained by boiling the samples in 1 SDS sam- PCR. Purified RNA was treated with RNase-free DNase I (Promega)
to remove residual DNA, and 1 g of purified DNA-free RNA wasple buffer (Laemmli buffer), fractionated onto SDS-PAGE, and elec-
troblotted to PVDF filters (Millipore) in 25 mM Tris base, 192 mM used for first-strand cDNA synthesis with SuperScript II RNase H
RT (Invitrogen) according to the manufacturer’s instructions. Quanti-glycine, 20% v/v methanol (pH 8.3) using a TransBlot cell (BioRad).
The membrane was blocked in 5% nonfat dry milk (Carnation) in tative PCR was performed as previously described (Orlando and
Paro, 1993) using an aliquot (1/20) of the RT reaction. PCR reactionsTBST (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% Tween-20) for
60 min, followed by incubation with the primary antibody for 60 contained [-32P]dATP (2.5 Ci for each 25 l reaction), and the PCR
products were detected by autoradiography after separation on amin. After three serial washings with TBST for 10 min, the antigen-
antibody complexes were visualized with the appropriate secondary 6% polyacrylamide gel. Sequences of the oligonucleotides used are
as follows: FRG1, FRG1-1f (5-TCTACAGAGACGTAGGCTGTCA-3)antibody (Jackson ImmunoResearch) conjugated to horseradish
peroxydase and a chemiluminescent system as recommended by and FRG1-1rb (5-CTTGAGCACGAGCTTGGTAG-3); FRG2, EX2BF
(5-CCAGAGTCCAGCTCATATCG-3) and SSC8 (5-CTCACAGGTAthe manufacturer (NEN).
AGTGGAGAATGG-3); ANT1, ANT1 (5-GTGCATTAAGTGGTCTTT
ATT-3) and ANT2 (5-TGTGGTTTAATAGACTATTCCTA-3); GAPDH,Electro-Mobility Shift Assay (EMSA) and Supershift
G3PDH 5 (5-ACCACAGTCCATGCCATCAC-3) and G3PDH 3The KpnI-D4Z4 unit plasmid, used to generate EMSA probes for the
(5-TCCACCACCCTGTTGCTGTA-3). The FRG2 oligos were kindlyexperiments shown in Figure 2, was kindly provided by L. Felicetti.
provided by R.R. Frants and S. Van der Maarel. FRG1 and ANT1For the EMSA experiments shown in Figure 4, oligonucleotide
primers are 4q35 specific. Closely related sequences to FRG2 areprobes were prepared by end-labeling double-stranded oligonucle-
present on chromosomes 1, 4, 8, 10, and 20; however, the FRG2otides covering the region of the minimal binding site. The se-
copy at 4q35 is the only one resistant to digestion with TaiI andquences of the oligonucleotides were as follows: WT, 5-CTCACCG
HhaI (R.R. Frants, personal communication). Therefore, to obtain aCCATTCATGAAGGGGTGGAGCCTGCCTG-3; MUT, 5-CTCACCG
4q35-specific signal, FRG2 PCR products were digested with bothCCgccCATGAAGGGGTGGAGCCTGCCTG-3 (mutated nucleotides
enzymes before electrophoresis.are reported in italics). DNA binding reactions were carried out in
20 l of 10 mM HEPES (pH 8), 10% glycerol, 50 mM KCl, 0.1 mM
EDTA, 0.25 mM DTT, 0.1 mg/ml poly(dI-dC), 0.1 mg/ml bovine serum Purification of GST-YY1
GST-YY1 expression vectors were kindly provided by Y. Shi, E. Seto,albumin, 20,000 cpm of radiolabeled probe. The samples were incu-
bated 30 min on ice in the presence of the indicated nuclear extract A. Usheva, D.M. Margolis, and T. Shenk. For purification, saturated
cultures of E. coli expressing the GST-YY1 fusion protein were di-or protein fraction. For competition assays, unlabeled probes were
added to the reaction mixture at the same time as the labeled probe. luted 1:20 with fresh media and incubated at 37C until OD at 600
nm was 0.6. IPTG was added to a final concentration of 0.2 mM,For supershift assays, binding reaction was assembled in the ab-
sence of radiolabeled probe. Antibodies were added to the binding and the bacteria were incubated at 37C for 4 hr. Bacteria were
harvested, washed once with STE (10 mM Tris [pH 8.0], 150 mMreaction and the samples were incubated 15 min at room tempera-
ture. Radiolabeled probe was added and the samples were incu- NaCl, 1 mM EDTA), and resuspended in STE containing 100 g/ml
of lysozyme. Following a 15 min incubation on ice, DTT was addedbated for additional 30 min on ice. Reaction mixtures were loaded
in the cold room onto 6% native polyacrylamide gels containing to a final concentration of 5 mM. N-Lauryl Sarcosine was added to
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a final concentration of 1.5% (from a 10% stock in STE), and the Bennett, S.T., Lucassen, A.M., Gough, S.C., Powell, E.E., Undlien,
D.E., Pritchard, L.E., Merriman, M.E., Kawaguchi, Y., Dronsfield,bacteria were sonicated on ice until the solution was clear (1
min). Triton X-100 was added to a final concentration 3%. Following M.J., Pociot, F., et al. (1995). Susceptibility to human type 1 diabetes
at IDDM2 is determined by tandem repeat variation at the insulincentrifugation, the supernatant was added to glutathione agarose
beads (50% suspension in STE) for affinity purification. Fusion pro- gene minisatellite locus. Nat. Genet. 9, 284–292.
teins were eluted using 75 mM HEPES (pH 7.4), 150 mM NaCl, 10 Blair, I.P., Adams, L.J., Badenhop, R.F., Moses, M.J., Scimone, A.,
mM reduced glutathione, 5 mM DTT, and 2% N-octyl glucoside. Morris, J.A., Ma, L., Austin, C.P., Donald, J.A., Mitchell, P.B., and
Purified GST-YY1 was dialyzed against dialysis buffer (20 mM Schofield, P.R. (2002). A transcript map encompassing a susceptibil-
HEPES [pH 8], 20% glycerol, 100 mM KCl, 0.2 mM EDTA, 0.2 mM ity locus for bipolar affective disorder on chromosome 4q35. Mol.
PMSF, 0.5 mM DTT). Psychiatry, in press.
Boyd, K.E., Wells, J., Gutman, J., Bartley, S.M., and Farnham, P.J.
Antisense Morpholino Oligonucleotides (1998). c-Myc target gene specificity is determined by a post-DNA
Morpholino oligonucleotides (GeneTools) spanning the sequence of binding mechanism. Proc. Natl. Acad. Sci. USA 95, 13887–13892.
the AUG translational start site of human YY1 (5-CATGGCTGAGGG
Chung, J.H., Bell, A.C., and Felsenfeld, G. (1997). CharacterizationCTCCGCCGCCACG-3), HMGB2 (5-GGGTCTCCTTTACCCATGTT
of the chicken -globin insulator. Proc. Natl. Acad. Sci. USA 94,GACAG-3), nucleolin (5-GCGAGCTTCACCATGATGGCGGCGG-3),
575–580.or standard control oligonucleotides (5-CCTCTTACCTCAGTTA
Clark, L.N., Koehler, U., Ward, D.C., Wienberg, J., and Hewitt, J.E.CAATTTATA-3) were introduced into HeLa cells according to the
(1996). Analysis of the organisation and localisation of the FSHD-manufacturer’s special delivery protocol (Morcos, 2001). Oligonu-
associated tandem array in primates: implications for the origin andcleotide delivery was repeated at 48 hr intervals for a total of five
evolution of the 3.3 kb repeat family. Chromosoma 105, 180–189.times. Cells were maintained at exponential growth throughout the
entire procedure. Immunoblotting and quantitative RT-PCR analysis Dorner, A., and Schultheiss, H.P. (2000). The myocardial expression
was performed 48 hr after the last delivery. of the adenine nucleotide translocator isoforms is specifically al-
tered in dilated cardiomyopathy. Herz 25, 176–180.
Repression Assay Dunger, D.B., Ong, K.K., Huxtable, S.J., Sherriff, A., Woods, K.A.,
The vector pcDNA 3.1 (Invitrogen) was digested with KpnI and SmaI, Ahmed, M.L., Golding, J., Pembrey, M.E., Ring, S., Bennett, S.T.,
blunt-ended, and religated to obtain CMV-Neo. Tandem repeats of and Todd, J.A. (1998). Association of the INS VNTR with size at
the DBE sequence were produced as described (Ausubel et al., birth. ALSPAC study team. Avon longitudinal study of pregnancy
2001) and cloned into the NheI site of CMV-Neo to obtain CMV- and childhood. Nat. Genet. 19, 98–100.
DBE-Neo. A spacer sequence equivalent in length to six DBE repeats
Eng, J.K., McCormack, A.L., and Yates, J.R., Iii. (1994). An approachwas generated by digesting pBluescript SK (Stratagene) with SpeI
to correlate tandem mass spectral data of peptides with amino acidand PvuII and was cloned into NheI/HindIII-digested CMV-Neo that
sequences in a protein database. J. Am. Soc. Mass Spectrom. 5,had been blunt-ended at the HindIII site to obtain CMV-Spacer-Neo.
976–989.Each construct was verified by sequencing.
For the repression assay, each construct was linearized with PvuI Fisher, J., and Upadhyaya, M. (1997). Molecular genetics of facio-
and transfected into HeLa cells in 6-well plates with Effectene ac- scapulohumeral muscular dystrophy (FSHD). Neuromuscul. Disord.
cording to the manufacturer’s instructions (Qiagen). Forty-eight 7, 55–62.
hours after transfection, one-third of each well was passed in 100 Gabriels, J., Beckers, M.C., Ding, H., De Vriese, A., Plaisance, S.,
mm plates, and G418 (1 mg/ml, Calbiochem) was added to the van der Maarel, S.M., Padberg, G.W., Frants, R.R., Hewitt, J.E.,
media. Two weeks later, colonies were fixed and stained with Collen, D., and Belayew, A. (1999). Nucleotide sequence of the par-
Giemsa, and the number of G418-resistant cells counted. Experi- tially deleted D4Z4 locus in a patient with FSHD identifies a putative
ments were repeated in triplicate, using two different plasmid prepa- gene within each 3.3 kb element. Gene 236, 25–32.
rations.
Goto, K., Lee, J.H., Matsuda, C., Hirabayashi, K., Kojo, T., Nakamura,
A., Mitsunaga, Y., Furukawa, T., Sahashi, K., and Arahata, K. (1995).
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